We are pleased to announce that U.S. Senator Angus King (I-ME) has received the Prescription Justice 5-star rating based on his full support of the organization’s Policy Platform to lower drug prices here and expand access to safe and affordable medication from other countries. Senator King’s 5-star rating reflects his unwavering support of commonsense policy solutions to end the prescription drug affordability crisis. Members of Congress get one star for their positions on the following:
1. Recognizes that the United States is suffering from a crisis of high drug prices?
2. Ending the ban that prevents Medicare from negotiating lower drug prices with pharmaceutical companies;
3. Making reverse payment arrangements between brand and generic companies, also known as “pay-for-delay” illegal;
4. Legalizing the importation of lower-cost medication from Canada and other countries with similarly strict pharmaceutical regulations; and 5. Using reasonable, commonsense, and compassionate enforcement discretion to permit individuals to import small quantities of affordable medication to fill prescriptions. (more…)
Prescription Justice has endorsedRyan Watts for the U.S. House of Representatives in the 6th District of North Carolina based on his pro-patient/pro-consumer stance to address the prescription drug price crisis in America.
Ryan Watts fully supports the Prescription Justice Policy Platform to permit Medicare to negotiate drug prices; ending “pay-for-delay” deals by pharmaceutical companies that prevent lower cost generics from coming to market; legalizing importation of lower-cost and safe medication; and expressly permitting personal importation now from licensed pharmacies as a lifeline of affordable medication. (more…)
A group of over 50 healthcare providers, including physicians, nurses and physician assistants, have come together to demand the federal government stop any action that would restrict access to lifesaving medications through personal prescription importation.
In a letter sent to President Donald Trump, members of Congress and the Food and Drug Administration (FDA), the healthcare providers expressed their alarm over FDA’s action in Florida against offices that primarily serve older Americans who prefer in-person assistance with purchasing medications from Canada and other countries, rather than using an internet site. Last year, FDA agents armed with search warrants notified the office owners that importing drugs is illegal and those who help “administer” such drugs could face fines or jail time. Yet, according to its owners, these offices do not dispense or administer medication to patients. (more…)
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don't take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Over the past year, we have concentrated our efforts and resources on advocating for regulatory and legislative reforms and commonsense policies to lower domestic drug prices and expand access to lower cost medication from pharmacies in other countries. (more…)
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump's nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt's Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar's confirmation.
During recent testimony before the Senate Health, Education, Labor and Pension Committee hearing on Stabilizing the Affordable Care Act Marketplace, AARP became the largest consumer organization to publicly support the prescription drug policy solutions reflected in Prescription Justice’s policy platform. AARP supports commonsense policy reforms to allow Medicare to negotiate drug prices, end pay-for-delay deals that delay entry of generic drugs into the marketplace, and increase access to lower cost medications through safe prescription drug importation. As part of a larger set of priorities for protecting and strengthening the healthcare system, AARP boldly declared that any changes to the healthcare law must include solutions to address rising prescription drug costs. (more…)
Recently, The Hill featured the Op-Ed, A tale of two drug bills — one proposed bill will worsen the drug prices crisis, by Gabriel Levitt, President of Prescription Justice. Mr. Levitt’s Op-Ed provides an insightful look at legislation targeting two distinct public health problems, but only one has the capacity to inflict further devastation from the public health crisis that is high drug prices.
The Synthetics Trafficking & Overdose Prevention Act of 2017 (STOP Act), introduced by Sen. Rob Portman (R- OH) aims to stop the flow of the highly addictive synthetic opioid fentanyl from coming into the U.S. by requiring the U.S. Postal Service (USPS) to obtain information about packages coming from foreign sources. Unlike private carriers such as UPS and FedEx, the USPS does not currently require advanced electronic customs data from much of the mail received at its International Mail centers.
The Brussels Principles underscore the importance of the international online marketplace as a lifeline of affordable medication for the millions of people forced to go without necessary treatment due to drug cost and availability.
On March 31st, 2017, Prescription Justice organized a panel for the RightsCon 2017 conference in Brussels, which addressed protecting online access to safe and affordable medication. The organizers of RightsCon just published their outcomes document in which Prescription Justice’s effort to bring together both medicines access and Internet freedom advocates was recognized.
At that conference, the participants discussed a set of draft principles pertaining to medication sales over the Internet and prescription drug importation. The prevailing position among the panelists was that initiatives funded by the pharmaceutical industry that affect access to medicines on the Internet were detrimental to the cause of prescription drug affordability.